Profile data is unavailable for this security.
About the company
argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.
- Revenue in EUR (TTM)238.97m
- Net income in EUR-827.00m
- Incorporated2008
- Employees650.00
- Locationargenx SEWillemstraat 5BREDA 4811 AHNetherlandsNLD
- Phone+31 763030488
- Websitehttps://www.argenx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Qiagen NV | 2.03bn | 421.83m | 10.24bn | 6.20k | 24.22 | 3.33 | 16.84 | 5.06 | 1.83 | 1.83 | 8.79 | 13.30 | 0.3545 | 2.38 | 6.40 | 336,031.50 | 7.38 | 3.69 | 9.28 | 4.28 | 64.73 | 65.54 | 20.83 | 11.68 | 1.62 | 23.13 | 0.4076 | -- | 20.39 | 10.97 | 42.71 | 44.84 | 17.07 | -- |
| Croda International Plc | 2.35bn | 800.66m | 10.94bn | 6.14k | 13.68 | 4.11 | 11.64 | 4.66 | 5.08 | 5.08 | 14.89 | 16.91 | 0.5686 | 2.71 | 4.97 | 339,511.00 | 19.52 | 11.17 | 22.63 | 13.16 | 48.22 | 43.71 | 34.33 | 16.39 | 2.25 | 24.36 | 0.3202 | 61.78 | 35.91 | 8.73 | 59.13 | 10.28 | 8.53 | 5.70 |
| BioMerieux SA | 3.46bn | 552.00m | 11.07bn | 13.08k | 20.08 | 3.22 | 13.78 | 3.20 | 4.66 | 4.66 | 29.20 | 29.03 | 0.7523 | 2.23 | 5.93 | 264,606.90 | 11.92 | 9.78 | 15.18 | 13.13 | 57.42 | 55.47 | 15.85 | 12.69 | 1.32 | 60.64 | 0.1441 | 14.14 | 8.27 | 9.93 | 48.64 | 27.40 | 4.48 | 20.59 |
| Eurofins Scientific SE | 6.86bn | 823.70m | 12.57bn | 61.00k | 15.84 | 2.67 | 8.81 | 1.83 | 4.12 | 3.21 | 34.27 | 24.42 | 0.7248 | 31.28 | 4.92 | 118,238.70 | 9.05 | 7.66 | 11.39 | 9.73 | 25.13 | 23.52 | 12.49 | 11.80 | 1.25 | 10.16 | 0.4124 | 16.22 | 23.51 | 21.50 | 50.07 | 39.88 | 21.07 | 37.97 |
| UCB SA | 5.92bn | 887.00m | 14.35bn | 8.56k | 15.97 | 1.57 | 10.95 | 2.42 | 4.62 | 4.62 | 30.81 | 46.94 | 0.4037 | 1.82 | 4.79 | 691,975.30 | 6.05 | 7.39 | 7.38 | 9.30 | 73.09 | 74.34 | 14.99 | 16.73 | 0.828 | 36.69 | 0.2528 | 28.56 | 8.04 | 6.85 | 44.13 | 14.21 | 29.00 | 2.48 |
| argenx SE | 238.97m | -827.00m | 18.91bn | 650.00 | -- | -- | -- | 79.13 | -15.90 | -15.90 | 4.50 | -- | -- | -- | -- | 367,652.60 | -- | -20.19 | -- | -22.86 | 83.75 | -- | -346.06 | -191.43 | -- | -7.70 | -- | -- | 1,105.73 | 98.16 | 32.90 | -- | 163.70 | -- |
| Genmab A/S | 1.61bn | 759.96m | 23.57bn | 1.56k | 31.01 | 6.50 | -- | 14.63 | 85.71 | 85.71 | 181.62 | 408.67 | 0.4385 | -- | 2.94 | 9,890,264.00 | 20.68 | 18.87 | 22.68 | 20.07 | -- | -- | 47.17 | 42.62 | -- | -- | 0.023 | 0.00 | -16.11 | 36.10 | -36.78 | 20.44 | 50.07 | -- |
| Merck KGaA | 21.79bn | 3.47bn | 23.59bn | 63.72k | 22.87 | 2.81 | 4.49 | 1.08 | 7.98 | 7.98 | 50.08 | 65.00 | 0.4598 | 1.90 | 5.18 | 361,073.30 | 7.36 | 5.00 | 9.24 | 6.60 | 62.35 | 63.17 | 16.00 | 12.09 | 0.8588 | 26.73 | 0.28 | 9.16 | 12.28 | 5.56 | 53.75 | 13.40 | 10.88 | 9.04 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 01 Mar 2022 | 1.98m | 3.58% |
| Federated Global Investment Management Corp.as of 18 Oct 2022 | 1.65m | 2.98% |
| Wellington Management Co. LLPas of 01 Mar 2022 | 1.55m | 2.79% |
| Baillie Gifford & Co.as of 01 Mar 2022 | 1.40m | 2.53% |
| Norges Bank Investment Managementas of 31 Dec 2021 | 1.20m | 2.18% |
| RTW Investments LPas of 08 Jul 2022 | 1.06m | 1.91% |
| BlackRock Fund Advisorsas of 05 Jan 2023 | 911.92k | 1.65% |
| Bellevue Asset Management AGas of 30 Sep 2022 | 892.50k | 1.61% |
| Polar Capital LLPas of 30 Nov 2022 | 447.95k | 0.81% |
| BlackRock Advisors (UK) Ltd.as of 05 Jan 2023 | 384.51k | 0.70% |
